Evidence map›Paper›PMID 33105058›Full record

ArticleThe oncologist2021

A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26-104/RFASE in Patients with Advanced Solid Malignancies.

Ruben S A Goedegebuure, Madelon Q Wentink, Hans J van der Vliet, Peter Timmerman, Arjan W Griffioen, Tanja D de Gruijl, Henk M W Verheul

Open access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Ruben S A GoedegebuureAmsterdam UMC, VUmc location, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Madelon Q WentinkAmsterdam UMC, VUmc location, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Hans J van der VlietAmsterdam UMC, VUmc location, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Peter TimmermanPepscan, Lelystad, The Netherlands.
Arjan W GriffioenAmsterdam UMC, VUmc location, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Tanja D de GruijlAmsterdam UMC, VUmc location, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Henk M W VerheulRadboud UMC, Department of Medical Oncology, Nijmegen, The Netherlands.ORCID 0000-0001-5981-922X
Amsterdam University Medical Centers · NLCancer Center AmsterdamLava Therapeutics (Netherlands) · NLPepscan (Netherlands) · NLRadboud University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

lessons learnedThe novel therapeutic vaccine hVEGF

backgroundTargeting vascular endothelial growth factor-A (VEGF) is a well-established anticancer therapy. We designed a first-in-human clinical trial to investigate the safety and immunogenicity of the novel vaccine hVEGF

methodsPatients with advanced solid malignancies with no standard treatment options available were eligible for this phase I study with a 3+3 dose-escalation design. On days 0, 14, and 28, patients received intramuscular hVEGF

resultsEighteen of 27 enrolled patients received three immunizations in six different dose-levels up to 1,000 μg hVEGF

conclusionDespite having an attractive safety profile, hVEGF

Indexed as

NeoplasmsVaccinesFatty AcidsHumansRaffinoseSulfatesVascular Endothelial Growth Factor AFatty AcidsRaffinoseSulfatesVaccinesVascular Endothelial Growth Factor AAngiogenesis inhibitorsPeptite vaccineVascular Endothelial Growth Factor A

Identifiers

PMID33105058
PMCPMC7873342
OpenAlexW3093949271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.